Elevate your Research with AI-Powered Digital Pathology
From Pre-clinical research to late-stage clinical trials, HistoIndex provides cutting-edge, stain-free digital pathology solutions that enhance precision and drive successful outcomes.
Advanced Stain-Free Imaging Technology
Supplementing Second Harmonic Generation microscopy with AI assessments, our platforms analyze liver biopsies to accurately quantify fibrosis – unlocking continuous metrics that sensitively detect subtle histological changes that may be missed by stains.
With over a decade of expertise, we have scanned and analyzed more than 10,000 patient biopsy samples from MASH clinical trials in collaboration with leading pharma and biotech partners, often revealing insights of drug action not detectable by standard assessments.
Refer to our publications page here.
Pre-Clinical Studies
Achieve greater accuracy, reproducibility, and efficiency in your preclinical studies, accelerating the path to clinical success.
- Early & Accurate Disease Detection – Identify minute pathological changes in MASH and other disease models with a fail-fast system
- AI-Powered Quantitative Digital Pathology – Continuous, stain-free measurement of fibrosis, septa, steatosis, and ballooning for precise histology-based assessment
- Zonal & Localization Analysis – Gain deeper understanding into disease progression and drug mechanisms of action with spatial insights
- Seamless Preclinical-to-Clinical Transition – Ensure consistency with an AI-based platform that translates findings from animal models to human biopsy quantification
Clinical Studies
HistoIndex collaborates with leading pharmaceutical players, biotech companies, and research institutes to drive mechanistic and biomarker discovery through AI-powered analysis. Enabled by our sensitive stain-free imaging, our fully quantitative and granular analysis of generated histology images offers deep understanding into fibrosis regression, disease progression prediction, and clinical outcome assessments.
Our stain-free, AI-based platform supports both academic and industry-sponsored clinical studies, ensuring seamless data translation across biomarker discovery and drug development phases.
Clinical Trials
We are powering clinical trials with AI-driven digital pathology to enhance drug evaluation and regulatory success.
HistoIndex is a trusted partner in clinical trials, contributing to FDA Phase 2b/3 MASH trials. Our stain-free, AI-based platform has been utilized as primary, secondary, and exploratory endpoints in leading studies
Why Integrate AI Digital Pathology into Your Trials?
- Endpoint Quantification & Biomarker Discovery
- Provide robust, quantitative data to support regulatory approvals.
- Improve pathologist reproducibility in staging/scoring, especially in borderline cases
- Reduce “no change” cases and increase measurable treatment response
Our technology eliminates inter-reader variability and enhances reproducibility in histological assessments. By providing objective, quantitative endpoints, we help accelerate decision-making and reduce trial risk—unlocking the full potential of your investigational therapy.
Research-Based Services FAQs
HistoIndex offers advanced research-based services that leverage stain-free digital pathology and AI to support pre-clinical studies, clinical research, and late-stage clinical trials, enabling objective quantification of histological features such as fibrosis.
AI-powered digital pathology enables automated, quantitative analysis of high-resolution tissue images, detecting subtle morphological changes and biomarkers that may be missed by traditional methods, improving reproducibility and depth of insight across studies.
In pre-clinical research, HistoIndex identifies early and minute pathological changes, quantifies features like fibrosis and steatosis, and provides continuous, quantitative metrics with seamless translation from animal models to human tissue analysis.
Yes, HistoIndex collaborates with pharmaceutical companies, biotech firms, and academic researchers to deliver AI-enhanced histological analysis for clinical studies, helping with mechanistic insights, biomarker discovery, and robust quantification of disease features.
HistoIndex powers clinical trials by supplying quantitative digital endpoints and objective biomarkers derived from stain-free imaging and AI, supporting regulatory decision-making, reducing variability, and enhancing measurable treatment responses.
Yes, the platform’s granular histological quantification and spatial analysis enable researchers to discover and validate novel biomarkers, correlating microscopic tissue features with disease progression and therapeutic response.
HistoIndex combines Second Harmonic Generation (SHG) stain-free imaging with AI algorithms like qFibrosis® to extract rich quantitative data from tissue biopsies, providing deep insights into tissue architecture and pathology.
Yes, their digital pathology outputs have been used as primary, secondary, and exploratory endpoints in Phase 2b/3 clinical trials, helping improve endpoint quantification and increase trial success potential.
HistoIndex’s services are designed to complement standard pathology and research workflows and can integrate with existing imaging and data pipelines, ensuring continuity across study phases.
The high-quality, label-free images generated through SHG/TPEF imaging form the foundation for multiple quantitative assessments - not only qFibrosis®. Contact us for more details.